bioAffinity holder sells 41,529 shares, buys 17,873
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. (BIAF) reported that 10% owner HRT Financial LP bought and sold common stock from September 22, 2026, through October 1, 2026. On October 1, HRT Financial LP purchased 17,873 shares at a weighted-average $6.5436 per share and sold 41,529 shares at a weighted-average $6.4466 per share. It also reported warrant purchases and sales; each warrant is exercisable for 1/450 of a common share at an exercise price of $3,645 per whole share. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F26, F29 | 17,873 | $6.5436 | $117K |
| Sale | Common Stock F27, F29 | 41,529 | $6.4466 | $268K |
| Purchase | Common Stock F24, F28 | 12,125 | $6.7775 | $82K |
| Sale | Common Stock F25, F28 | 20,432 | $6.7638 | $138K |
| Purchase | Warrant (rights to buy) F22, F23 | 1 | $0.32 | $0.32 |
| Purchase | Common Stock F18, F23 | 8,894 | $6.8647 | $61K |
| Purchase | Common Stock F19, F23 | 13,840 | $7.1206 | $99K |
| Sale | Common Stock F20, F23 | 18,627 | $6.8259 | $127K |
| Sale | Common Stock F21, F23 | 2,201 | $7.0518 | $16K |
| Purchase | Warrant (rights to buy) F22, F23 | 2 | $0.38 | $0.76 |
| Purchase | Common Stock F15, F23 | 10,734 | $7.6438 | $82K |
| Purchase | Common Stock F23 | 2 | $8.09 | $16.18 |
| Sale | Common Stock F16, F23 | 13,856 | $7.5676 | $105K |
| Sale | Common Stock F17, F23 | 152 | $8.1012 | $1K |
| Sale | Warrant (rights to buy) F13, F14 | 1 | $0.26 | $0.26 |
| Purchase | Common Stock F11, F14 | 7,271 | $7.8065 | $57K |
| Sale | Common Stock F12, F14 | 9,111 | $7.8588 | $72K |
| Sale | Warrant (rights to buy) F13, F14 | 6 | $0.26 | $1.56 |
| Purchase | Common Stock F9, F14 | 30,065 | $7.668 | $231K |
| Sale | Common Stock F10, F14 | 27,246 | $7.755 | $211K |
| Purchase | Warrant (rights to buy) F7, F8 | 1 | $0.32 | $0.32 |
| Sale | Warrant (rights to buy) F7, F8 | 2 | $0.31 | $0.62 |
| Purchase | Common Stock F3, F8 | 7,509 | $7.9123 | $59K |
| Purchase | Common Stock F4, F8 | 11,002 | $8.1438 | $90K |
| Sale | Common Stock F5, F8 | 11,129 | $7.9399 | $88K |
| Sale | Common Stock F6, F8 | 10,859 | $8.1074 | $88K |
| Purchase | Common Stock F1, F8 | 18,929 | $8.5879 | $163K |
| Sale | Common Stock F2, F8 | 7,077 | $8.6306 | $61K |
Footnotes (29)
- F1. Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*
- F2. Weighted average price; executed in multiple trades at prices from $8.405 to $8.74.*
- F3. Weighted average price; executed in multiple trades at prices from $7.78 to $7.995.*
- F4. Weighted average price; executed in multiple trades at prices from $8.00 to $8.80.*
- F5. Weighted average price; executed in multiple trades at prices from $7.86 to $7.99.*
- F6. Weighted average price; executed in multiple trades at prices from $8.00 to $8.84.*
- F7. Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.
- F8. Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.
- F9. Weighted average price; executed in multiple trades at prices from $7.50 to $7.95.*
- F10. Weighted average price; executed in multiple trades at prices from $7.59 to $7.98.*
- F11. Weighted average price; executed in multiple trades at prices from $7.67 to $7.95.*
- F12. Weighted average price; executed in multiple trades at prices from $7.74 to $7.96.*
- F13. Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.
- F14. Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.
- F15. Weighted average price; executed in multiple trades at prices from $7.33 to $7.93.*
- F16. Weighted average price; executed in multiple trades at prices from $7.33 to $7.92.*
- F17. Weighted average price; executed in multiple trades at prices from $8.10 to $8.13.*
- F18. Weighted average price; executed in multiple trades at prices from $6.68 to $6.99.*
- F19. Weighted average price; executed in multiple trades at prices from $7.01 to $7.50.*
- F20. Weighted average price; executed in multiple trades at prices from $6.69 to $6.99.*
- F21. Weighted average price; executed in multiple trades at prices from $7.00 to $7.60.*
- F22. Each warrant is exercisable for 1/450 of a share of Common Stock; the exercise price shown is per whole share, as adjusted for the issuer's reverse stock splits. Underlying amounts are rounded to four decimal places.
- F23. Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.
- F24. Weighted average price; executed in multiple trades at prices from $6.56 to $6.99.*
- F25. Weighted average price; executed in multiple trades at prices from $6.59 to $6.99.*
- F26. Weighted average price; executed in multiple trades at prices from $6.23 to $6.88.*
- F27. Weighted average price; executed in multiple trades at prices from $6.07 to $6.865.*
- F28. Represents the reporting person's beneficial ownership at the end of the transaction date, after all transactions on that date, including transactions not reported on this form.
- F29. Represents the reporting person's beneficial ownership immediately after the transaction that reduced its beneficial ownership to 10% or less of the outstanding Common Stock, ending the period in which the transactions reported on this line occurred, including transactions not reported on this form.
Key Figures
Key Terms
Warrant (rights to buy) technical
Weighted average price financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were HRT Financial LP's BIAF transactions on October 1?
What warrant transactions did HRT Financial LP report for BIAF?
AI-generated analysis. How Rhea-AI works. Not financial advice.